Dasatinib is a second generation tyrosine kinase inhibitor that shares the same binding site on the BCR:ABL cluster region as imatinib, but maintains activity despite imatinib resistance, with more higher potency than imatinib. Dasatinib also inhibits SRC kinases, which are tyrosine kinases that mediate cellular differentiation, proliferation and survival. The terminal half-life of dasatinib is 3 to 5 hours, with elimination primarily via the liver and feces. Dasatinib is used in the treatment of chronic myeloid leukemia with resistance or intolerance to imatinib, and for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Side effects of dasatinib include myelosuppression, nausea and vomiting, headache, fluid retention, hypocal-cemia and pleural effusions.

Stop Headache Drug Free

Stop Headache Drug Free

If you are suffering from headaches, you can make the pain stop just by following some basic but little known principles. Take 15 minutes browsing through this guide and you'll find dozens of tips to gain control in the battle against headache pain.

Get My Free Audio Book

Post a comment